Modeling of human tumor xenografts and dose rationale in oncology

Drug Discovery Today: Technologies

Volumn 10, Issue 3, 2013, Pages

  Simeoni, Monica ^a   De Nicolao, Giuseppe ^b   Magni, Paolo ^b   Rocchetti, Maurizio ^c   Poggesi, Italo ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Dipartimento di Ingegneria Industriale e dell'Informazione   (Italy)

^c Independent Consultant   (Italy)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CRIZOTINIB; DOCETAXEL; FLUOROURACIL; GALUNISERTIB; IRINOTECAN; METHOTREXATE; PACLITAXEL; PICTILISIB; TDM 1; TRASTUZUMAB; UFT; UNCLASSIFIED DRUG;

DATA ANALYSIS; DRUG DOSE REGIMEN; DRUG SCREENING; EXPERIMENTAL MODEL; HUMAN; MATHEMATICAL MODEL; NONHUMAN; REVIEW; TUMOR GROWTH; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879247519     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2012.07.004     Document Type: Review

References (69)

1. M. Liu, and D. Hicklin Human tumor xenograft efficacy models B.A. Teicher, Tumor Models in Cancer Research, Cancer Drug Discovery and Development 2011 Springer Science+Business Media
2. P.L. Bonate Modeling tumor growth in oncology P.L. Bonate, D.R. Howard, Pharmacokinetics in Drug Development 2011 American Association of Pharmaceutical Scientists, LLC
3. O.E. Della Pasqua PKPD and disease modeling: concepts and applications to oncology H.H.C. Kimko, C.C. Peck, Clinical Trial Simulations 2011 AAPS Advances in the Pharmaceutical Sciences Series 1, Springer Science + Business Media, LLC
4. D.L. Woodhouse Chemotherapy investigations in cancer; with reference to the influence of certain organic dibasic acids, diamino compounds and nitro compounds on tumors in mice Cancer Res. 7 1947 398 401
5. J. Mattern Human tumor xenografts as model for drug testing Cancer Metastasis Rev. 7 1988 263 284
6. J. Rygaard Heterotransplantation of a human malignant tumour to the mouse mutant 'nude' Acta Pathol. Microbiol. Scand. 77 1969 758 760
7. M.C. Bissery Experimental antitumor activity and pharmacokinetics of camptothecin analog irinotecan (CPT-11) in mice Anticancer Drugs 7 1996 437 460
8. M.G. Hollingshead Antitumor efficacy testing in rodents J. Natl. Cancer Inst. 100 2008 1500 1510
9. L.R. Kelland Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development Eur. J. Cancer 40 2004 827 836
10. J.C. Walrath Genetically engineered mouse models in cancer research Adv. Cancer Res. 106 2010 113 164
11. M. Rocchetti Pharmacokinetic-pharmacodynamic model for predicting tumour growth inhibition in mice: a useful tool in oncology drug development Basic Clin. Pharmacol. Toxicol. 2005 265 268
12. T. Voskoglou-Nomikos Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models Clin. Cancer Res. 9 2003 4227 4239
13. M. Marušić Mathematical models of tumor growth The Lecture Presented at the Mathematical Colloquium in Osijek Organized by Croatian Mathematical Society - Division Osijek June 7, 1996 1996
14. A.K. Laird Dynamics of tumor growth Br. J. Cancer 18 1964 490 502
15. Simpson-Herren, and Lloyd Kinetic parameter and growth curves for experimental tumor systems Cancer Chemotherapy Rep. 54 1970 143 174
16. P.W. Sullivan, and S.E. Salmon Kinetics of tumor growth and regression in IgG multiple myeloma J. Clin. Invest. 51 1972 1697 1708
17. L. Norton Predicting the course of Gompertzian growth Nature (Lond.) 264 1976 542 545
18. L. Norton, and R. Simon Growth curve of an experimental solid tumor following radiotherapy J. Natl. Cancer Inst. (Bethesda) 58 1977 1735 1741
19. R. Simon, and L. Norton The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens Nat. Clin. Pract. Oncol. 3 2006 406 407
20. M. Simeoni Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents Cancer Res. 64 2004 1094 1101
21. P. Magni A mathematical model to study the effects of drug administration on tumor growth dynamics Math. Biosci. 200 2006 127 151
22. E.D. Lobo, and J.P. Balthasar Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro AAPS PharmSci. 4 2002 E42
23. J. Yang Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems AAPS J. 12 2010 1 10
24. P. Magni A minimal model of tumor growth inhibition IEEE Trans. Biomed. Eng. 55 2008 2683 2690
25. N.L. Jumbe Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice J. Pharmacokinet. Pharmacodyn. 37 2010 221 242
26. J.H. Sung A combined pharmacokinetic-pharmacodynamic (PK-PD) model for tumor growth in the rat with UFT administration J. Pharm. Sci. 98 2009 1885 1904
27. K. Goteti Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents J. Cancer Chemother. Pharmacol. 66 2010 245 254
28. G. Koch Modeling of tumor growth and anticancer effects of combination therapy J. Pharmacokinet. Pharmacodyn. 36 2009 179 197
29. M. Rocchetti Testing additivity of anticancer agents in pre-clinical studies: a PK/PD modelling approach Eur. J. Cancer 45 2009 3336 3346
30. L. Bueno Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice Eur. J. Cancer 44 2008 142 150
31. S. Yamazaki Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models Drug Met. Disp. 36 2008 1267 1274
32. L. Salphati Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941 Drug Met. Disp. 38 2010 1436 1442
33. J.E. Kalns Design and analysis of in vitro antitumor pharmacodynamic studies Cancer Res. 55 1995 5315 5322
34. N.J. Millenbaugh A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect Cancer Chemother. Pharmacol. 45 2000 265 272
35. M. Germani In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time Cancer Chemother. Pharmacol. 52 2003 Dec 507 513
36. F. Del Bene A model-based approach to the in vitro evaluation of anticancer activity Cancer Chemother. Pharmacol. 63 2009 827 836
37. T. Roose Mathematical models of avascular tumor growth SIAM Rev. 49 2008 179 208
38. J.S. Lowengrub Nonlinear modelling of cancer: bridging the gap between cells and tumours Nonlinearity 23 2010 R1 R91
39. H.M. Byrne Dissecting cancer through mathematics: from the cell to the animal model Nat. Rev. Cancer 10 2010 221 230
40. M.R. Owen Mathematical modelling of the use of macrophages as vehicles for drug delivery to hypoxic tumour sites J. Theor. Biol. 226 2004 377 391
41. Y. Jiang A multiscale model for avascular tumor growth Biophys. J. 89 2005 3884 3894 Erratum in: Biophys J. 91(2): 775
42. B. Ribba A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents J. Theor. Biol. 243 2006 532 541
43. B. Ribba A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies J. Theor. Biol. 3 2006 7
44. Z. Bajzer Conceptual frameworks for mathematical modeling of tumor growth dynamics Math. Comput. Model. 23 1996 31 46
45. N. Bellomo, and L. Preziosi Modeling and mathematical problems related to tumor evolution and its interaction with the immune system Math. Comput. Model. 32 2000 m413 m452
46. B. Basse, and P. Ubezio A Generalised age- and phase-structured model of human tumour cell populations both unperturbed and exposed to a range of cancer therapies Bull. Math. Biol. 69 2007 1673 1690
47. Z. Wang Simulating non-small cell lung cancer with a multiscale agent-based model Theor. Biol. Med. Model. 4 2007 50
48. L. Zhang Multiscale agent-based cancer modeling J. Math. Biol. 58 2009 545 559
49. B. Ribba A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers Eur. J. Cancer 47 2011 479 490
50. L.B. Sheiner Estimation of population characteristics of pharmacokinetic parameters from routine clinical data J. Pharmacokin. Pharmacodyn. 5 1977 445 479
51. Poggesi, I. et al. (2004). Population modeling of tumor growth in untreated xenografted mice. Abstracts of the Annual Meeting of the Population Approach Group in Europe, Uppsala PAGE 13, Abstr 535 [ http://www.page-meeting. org/?abstract=535 ]
52. Simeoni, M. et al. Population modeling of tumor growth inhibition in vivo: application to anticancer drug development. Abstracts of the Annual Meeting of the Population Approach Group in Europe, Uppsala PAGE 13, PAGE 13 (2004) Abstr 503 [ http://www.page-meeting.org/?abstract=503 ]
53. T.G. Roberts The phase III trial in the era of targeted therapy: unraveling the go and no go decision J. Clin. Oncol. 19 2003 3683 3695
54. I. Poggesi Antitumor efficacytesting in rodents J. Natl. Cancer Inst. 101 2009 1592 1593
55. M. Rocchetti Predicting the active doses in humans from animal studies: a novel approach in oncology Eur. J. Cancer 12 2007 1862 1868
56. D. Ouellet Benefit-risk assessment: the use of clinical utility index Expert Opin. Drug Safety 9 2010 289 300
57. G. Bonadonna Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate and fluorouracil in operable breast cancer J. Clin. Oncol. 22 2004 1614 1620
58. M.L. Citron Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741 J. Clin. Oncol. 21 2003 1431 1439
59. Y. Wang Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development Clin. Pharmacol. Ther. 86 2009 167 174
60. L. Claret Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics J. Clin. Oncol. 27 2009 4103 4108
61. E.B. Hedican Modeling biomarker dynamics with implications for the treatment of prostate cancer Comput. Math. Methods Med. 8 2007 77 92
62. L. Zhang Concepts and challenges in quantitative pharmacology and model-based drug development AAPS J. 10 2008 552 559
63. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). S9 Nonclinical Evaluation for Anticancer Pharmaceuticals; March 2010
64. P.S. Jones, and D. Jones New regulatory framework for cancer drug development Drug Discov. Today 17 2012 227 231
65. US Food and Drug Administration Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products 2004 p. 24. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/ CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm113411.pdf
66. End-of-phase 2a meetings. FDA guidance for Industry; September 2009
67. European Medicines Agency-European Federation of Pharmaceutical Industries and Associations modelling and simulation workshop; 30/11/2011-01/12/2011, London (UK); http://www.ema.europa.eu/ema/index.jsp?curl= pages/news-and-events/events/2011/07/event-detail-000440.jsp&mid= WC0b01ac058004d5c3
68. E.E. Manolis New pathway for qualification of novel methodologies in the European Medicines Agency Proteomics Clin. Appl. 5 2011 248 255
69. R.L. Lalonde Model-based drug development Clin. Pharmacol. Ther. 82 2007 21 32